



14 septembre 2017 – LAAS, Toulouse

ElectroImmunoGeno therapy IL-12: Proof of concept on metastatic murine melanoma

Vaccination antitumorale par pIRE amplifiée par
expression d'IL12 par electrotransfert cutané

Pasquet L., Bellard E., Chabot S., Joncker N., Golzio M., Teissié J.

Supported by grants « Région recherche en transfert clinique, normalisation, et innovation interdisciplinaire en biosanté n° 11052700 et n° 13050740 »

Techno




Cancer

PIRE: Partial IRreversible
Electropermeabilisation
of the tumor

Tumor antigen exposure
and release

Weak activation dendritic cells:
Low impact on the immune system

Aims



Anti-tumoral immunogenic response


Cancer

Controlled expression
of an immunogenic
adjuvant in the
peritumoral skin.

Cancer


Amplified activation of
dendritic cells:
Strong immune response

PIRE




→ Reduction of the tumor volume by PIRE treatment → Apoptosis then necrosis

PIRE + pIL-12 GET




EIGT treatments induce partial B16F10 tumor regression and 5/12 complete regression (CR)

PIRE + pIL-12 GET




EIGT treatment slows down distant tumor growth.

PIRE + pIL-12 GET



EIGT induces a memory immune response

PIRE + pIL-12 GET



Tumor regression induced by EIGT depends on adaptive immune response

Biodistribution - GMO Safety

group control

Organs Days after IL12 injection	lungs	liver	spleen	kidneys	lymph nodes	skin	gonads
D15	no	no	no	no	no	no	no
D49	no	no	no	no	no	no	no




group GET

Organs Days after IL12 GET	lungs	liver	spleen	kidneys	lymph nodes	Skin pg/μg of tissue DNA	gonads
D15	no	no	no	no	no	0.8	no
D49	no	no	no	no	no	0.045	no

Plasmids were transiently present specifically at the site of the treatment

Conclusions and Perspectives



**Anti-tumoral immunogenic response
- after one single treatment**

Nous disposons de la technologie biophysique, des protocoles, de la fabrication des plasmides et avons établi la courte durée de vie du plasmide spécifiquement au site d'injection.



L'objectif est d'établir un partenariat avec des cliniciens pour mener un essai clinique chez l'homme.